As of 2026-03-14, the Relative Valuation of Ascelia Pharma AB (ACE.ST) is (18.84) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 2.94 SEK, the upside of Ascelia Pharma AB based on Relative Valuation is -742.0%.
The range of the Relative Valuation is (18.60) - (19.77) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 30.9x - 32.9x | 32.5x |
| Forward P/E multiples | 28.4x - 36.6x | 30.2x |
| Fair Price | (18.60) - (19.77) | (18.84) |
| Upside | -733.6% - -773.7% | -742.0% |
| Date | P/E |
| 2026-03-12 | -5.09 |
| 2026-03-11 | -4.88 |
| 2026-03-10 | -5.16 |
| 2026-03-09 | -4.79 |
| 2026-03-06 | -4.81 |
| 2026-03-05 | -4.82 |
| 2026-03-04 | -4.85 |
| 2026-03-03 | -4.78 |
| 2026-03-02 | -4.91 |
| 2026-02-27 | -5.22 |
| 2026-02-26 | -5.21 |
| 2026-02-25 | -4.97 |
| 2026-02-24 | -5.00 |
| 2026-02-23 | -5.07 |
| 2026-02-20 | -5.37 |
| 2026-02-19 | -5.36 |
| 2026-02-18 | -5.34 |
| 2026-02-17 | -5.19 |
| 2026-02-16 | -5.43 |
| 2026-02-13 | -5.07 |
| 2026-02-12 | -5.07 |
| 2026-02-11 | -4.88 |
| 2026-02-10 | -5.04 |
| 2026-02-09 | -4.87 |
| 2026-02-06 | -4.64 |
| 2026-02-05 | -4.58 |
| 2026-02-04 | -4.33 |
| 2026-02-03 | -4.43 |
| 2026-02-02 | -4.62 |
| 2026-01-30 | -4.40 |
| 2026-01-29 | -4.37 |
| 2026-01-28 | -4.53 |
| 2026-01-27 | -4.65 |
| 2026-01-26 | -4.82 |
| 2026-01-23 | -4.97 |
| 2026-01-22 | -4.85 |
| 2026-01-21 | -4.70 |
| 2026-01-20 | -5.27 |
| 2026-01-19 | -5.09 |
| 2026-01-16 | -5.25 |
| 2026-01-15 | -5.37 |
| 2026-01-14 | -5.34 |
| 2026-01-13 | -5.13 |
| 2026-01-12 | -5.26 |
| 2026-01-09 | -5.20 |
| 2026-01-08 | -5.28 |
| 2026-01-07 | -5.49 |
| 2026-01-05 | -5.20 |
| 2026-01-02 | -5.40 |
| 2025-12-30 | -5.35 |